Brookfield Asset Management Inc. Intra Cellular Therapies, Inc. Transaction History

Brookfield Asset Management Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Sep 25, 2023	SELL	$54.67 - $66.44 $3.54 Million - $4.31 Million	-64,824 Reduced 68.85%	29,323 $1.86 Million
Q2 2023 Aug 14, 2023	SELL	$54.67 - $66.44 $3.54 Million - $4.31 Million	-64,824 Reduced 68.85%	29,323 $1.86 Million
Q1 2023 Sep 25, 2023	BUY	$43.8 - $56.99 $2.84 Million - $3.69 Million	64,824 Added 221.07%	94,147 $5.1 Million
Q1 2023 May 15, 2023	BUY	$43.8 - $56.99 $2.81 Million - $3.66 Million	64,202 Added 214.4%	94,147 $5.1 Million
Q4 2022 Feb 14, 2023	SELL	$44.07 - $54.45 $829,265 - $1.02 Million	-18,817 Reduced 38.59%	29,945 $1.58 Million
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $2.08 Million - $2.93 Million	48,762 New	48,762 $2.27 Million
Q1 2022 May 16, 2022	BUY	$38.74 - $62.09 $989,419 - $1.59 Million	25,540 New	25,540 $1.56 Million

416

88.5M

284K

105K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12.1B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Brookfield Asset Management Inc. with notifications on news.